PURPOSE: Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR) and HER2 have been reported to be both dysregulated in this cancer. To evaluate the in vivo effect of binding both EGFR and HER2 with two therapeutic humanized monoclonal antibodies (mAb), we treated human pancreatic carcinoma xenografts, expressing high EGFR and low HER2 levels. EXPERIMENTAL DESIGN: Nude mice, bearing xenografts of BxPC-3 or MiaPaCa-2 human pancreatic carcinoma cell lines, were injected twice weekly for 4 weeks with different doses of anti-EGFR (matuzumab) and anti-HER2 (trastuzumab) mAbs either alone or in combination. The effect of the two mAbs, on HER receptor phosphorylation, was also studied in vitro by Western blot analysis. RESULTS: The combined mAb treatment significantly inhibited tumor progression of the BxPC-3 xenografts compared with single mAb injection (P = 0.006) or no treatment (P = 0.0004) and specifically induced some complete remissions. The two mAbs had more antitumor effect than 4-fold greater doses of each mAb. The significant synergistic effect of the two mAbs was confirmed on the MiaPaCa-2 xenograft and on another type of carcinoma, SK-OV-3 ovarian carcinoma xenografts. In vitro, the cooperative effect of the two mAbs was associated with a decrease in EGFR and HER2 receptor phosphorylation. CONCLUSIONS: Anti-HER2 mAb has a synergistic therapeutic effect when combined with an anti-EGFR mAb on pancreatic carcinomas with low HER2 expression. These observations may open the way to the use of these two mAbs in a large panel of carcinomas expressing different levels of the two HER receptors.
PURPOSE:Pancreatic carcinoma is highly resistant to therapy. Epidermal growth factor receptor (EGFR) and HER2 have been reported to be both dysregulated in this cancer. To evaluate the in vivo effect of binding both EGFR and HER2 with two therapeutic humanized monoclonal antibodies (mAb), we treated humanpancreatic carcinoma xenografts, expressing high EGFR and low HER2 levels. EXPERIMENTAL DESIGN:Nude mice, bearing xenografts of BxPC-3 or MiaPaCa-2 humanpancreatic carcinoma cell lines, were injected twice weekly for 4 weeks with different doses of anti-EGFR (matuzumab) and anti-HER2 (trastuzumab) mAbs either alone or in combination. The effect of the two mAbs, on HER receptor phosphorylation, was also studied in vitro by Western blot analysis. RESULTS: The combined mAb treatment significantly inhibited tumor progression of the BxPC-3 xenografts compared with single mAb injection (P = 0.006) or no treatment (P = 0.0004) and specifically induced some complete remissions. The two mAbs had more antitumor effect than 4-fold greater doses of each mAb. The significant synergistic effect of the two mAbs was confirmed on the MiaPaCa-2 xenograft and on another type of carcinoma, SK-OV-3 ovarian carcinoma xenografts. In vitro, the cooperative effect of the two mAbs was associated with a decrease in EGFR and HER2 receptor phosphorylation. CONCLUSIONS: Anti-HER2 mAb has a synergistic therapeutic effect when combined with an anti-EGFR mAb on pancreatic carcinomas with low HER2 expression. These observations may open the way to the use of these two mAbs in a large panel of carcinomas expressing different levels of the two HER receptors.
Authors: C Larbouret; B Robert; C Bascoul-Mollevi; F Penault-Llorca; A Ho-Pun-Cheung; S Morisseau; I Navarro-Teulon; J-P Mach; A Pèlegrin; D Azria Journal: Ann Oncol Date: 2009-11-04 Impact factor: 32.976
Authors: Ruth Maron; Bilha Schechter; Maicol Mancini; Georg Mahlknecht; Yosef Yarden; Michael Sela Journal: Proc Natl Acad Sci U S A Date: 2013-09-03 Impact factor: 11.205
Authors: Christine M Ardito; Barbara M Grüner; Kenneth K Takeuchi; Clara Lubeseder-Martellato; Nicole Teichmann; Pawel K Mazur; Kathleen E Delgiorno; Eileen S Carpenter; Christopher J Halbrook; Jason C Hall; Debjani Pal; Thomas Briel; Alexander Herner; Marija Trajkovic-Arsic; Bence Sipos; Geou-Yarh Liou; Peter Storz; Nicole R Murray; David W Threadgill; Maria Sibilia; M Kay Washington; Carole L Wilson; Roland M Schmid; Elaine W Raines; Howard C Crawford; Jens T Siveke Journal: Cancer Cell Date: 2012-09-11 Impact factor: 31.743
Authors: Tsipi Ben-Kasus; Bilha Schechter; Sara Lavi; Yosef Yarden; Michael Sela Journal: Proc Natl Acad Sci U S A Date: 2009-02-13 Impact factor: 11.205